49 related articles for article (PubMed ID: 37364156)
1. Enhancing the management of locally advanced head and neck malignancies and cases with local/neck recurrence and metastasis through the integration of anlotinib with concurrent radiochemotherapy.
Tie X; Li H; Gao L; Liu P; Gao Y; Jin M; Duan G; Yi Z
Anticancer Drugs; 2024 May; ():. PubMed ID: 38809804
[TBL] [Abstract][Full Text] [Related]
2. Sternum Metastases: From Case-Identifying Strategy to Multidisciplinary Management.
Carsote M; Terzea D; Vasilescu F; Cucu AP; Ciuche A; Nistor C
Diagnostics (Basel); 2023 Aug; 13(16):. PubMed ID: 37627957
[TBL] [Abstract][Full Text] [Related]
3. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy with anlotinib in a locally advanced and pulmonary metastasis PTC patient harboring TERT promoter and BRAF
Su YJ; Cheng SH; Qian J; Zhang M; Liu W; Zhan XX; Wang ZQ; Liu HD; Zhong XW; Cheng RC
Arch Endocrinol Metab; 2023 Jun; 67(6):e000659. PubMed ID: 37364156
[TBL] [Abstract][Full Text] [Related]
5. BRAF
Choi JH; Yu HW; Lee JK; Kim W; Choi JY; Na HY; Park SY; Ahn CH; Moon JH; Choi SI; Lee HY; Lee WW; Cha W; Jeong WJ
World J Surg Oncol; 2023 Feb; 21(1):49. PubMed ID: 36804879
[TBL] [Abstract][Full Text] [Related]
6. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
7. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
Huang M; Yan C; Xiao J; Wang T; Ling R
Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
[TBL] [Abstract][Full Text] [Related]
8. TERT Promoter Mutations and Tumor Persistence/Recurrence in Papillary Thyroid Cancer.
Myung JK; Kwak BK; Lim JA; Lee MC; Kim MJ
Cancer Res Treat; 2016 Jul; 48(3):942-7. PubMed ID: 26727717
[TBL] [Abstract][Full Text] [Related]
9. The Genetic Duet of
Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
[No Abstract] [Full Text] [Related]
10. Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAF
Su Y; Cheng S; Qian J; Zhang M; Li T; Zhang Y; Diao C; Zhang L; Cheng R
Front Oncol; 2021; 11():626076. PubMed ID: 33842329
[TBL] [Abstract][Full Text] [Related]
11. Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer: A case report.
Zhang Y; Deng X; Ding Z; Kang J; Wu B; Guo B; Fan Y
Medicine (Baltimore); 2021 Mar; 100(12):e25191. PubMed ID: 33761701
[TBL] [Abstract][Full Text] [Related]
12. Surgical treatment of locally advanced thyroid cancer.
Roka R
Innov Surg Sci; 2020 Mar; 5(1-2):27-34. PubMed ID: 33506091
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and the effect of radioiodine on patients with locally advanced differentiated thyroid cancer.
Yao Y; Cheng S; Xu X; Chen X; Chen W; Qian Y; Zhang Y
Ann Transl Med; 2020 Aug; 8(15):928. PubMed ID: 32953728
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
